The effectiveness of the surgical approach and drug-holiday on the treatment of bisphosphonate related osteonecrosis of the jaw patient
![]() |
Rhee, Seung-Hyun
(Department of oral and maxillofacial surgery, School of dentistry, Pusan National University)
Park, Kun-Hyo (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) Lee, Jae-Yeol (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) Kim, Yong-Deok (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) Shin, Sang-Hun (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) Chung, In-Kyo (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) Kim, Gyoo-Cheon (Department of Oral Anatomy, School of dentistry, Pusan National University) Kim, Uk-Kyu (Department of oral and maxillofacial surgery, School of dentistry, Pusan National University) |
1 | Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78. DOI |
2 | Coleman RE. Optimising treatment of bone metastases by arediaTM and zometaTM. Breast Cancer 2000;7:361-9. DOI |
3 | Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int 2007;18:1363-70. DOI |
4 | Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S et al. Bisphosphonate-related osteonecrosis of the jaw: Clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009;67:1904-13. DOI |
5 | The Korean Endocrine Society; The Korean Society of Bone Metabolism; The Korean Society of Osteoporosis; The Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ) -position statement of Korea.- J Korean Endocr Soc 2009;24:227-230. DOI |
6 | Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the Jaw-2014 update. 2014; |
7 | Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes. Oral Oncol 2013;49:977-83. DOI |
8 | Lee HK, Seo MH, Pang KM, Song SI, Lee JK. Comparative Study on Surgical and Conservative Management of Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) in Disease Stage 2. J Korean Assoc Maxillofac Plast Reconstr Surg 2013;35:302-309. |
9 | Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008;66:767-75. DOI |
10 | Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36. DOI |
11 | Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. DOI |
12 | Park HM, Lee ES, Kim SM. The use of osteoporosis medications in Korea in 2008. J Bone Metab 2009;16;87-93. |
13 | Marx RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. DOI |
14 | Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the american society for bone and mineral research. J Bone Miner Res 2007;22:1479-91. DOI |
15 | Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7. DOI |
16 | Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH et al. Bisphosphonates-related osteonecrosis of the jaw in korea: A preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13. DOI |
17 | Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B et al. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-- 2009 update. J Oral Maxillofac Surg 2009;67:2-12. DOI |
18 | Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: A potential alternative to drug-holidays. Gen Dent 2013;61:33-8. |
19 | Wanger G, Gorby Y, El-Naggar MY, Yuzvinsky TD, Schaudinn C, Gorur A et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. 2013;115:71-8. DOI |
20 | Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: Preliminary results of a prospective study. Photomed Laser Surg 2010;28:179-84. DOI |
21 | Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in australia. J Oral Maxillofac Surg 2007;65:415-23. DOI |
22 | Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-53. DOI |
23 | Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62. DOI |
24 | Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7. DOI |
25 | Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605-9. DOI |
26 | Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:2644-8. DOI |
27 | Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167-73. DOI |
28 | Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z et al. Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-8. DOI |
29 | Marx RE, Cillo JE,Jr, Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. DOI |
30 | Song JW, Kim KH, Song JM, et al. Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg 2011;37:1-8. DOI |
31 | Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol 2012;30:369-78. DOI |
![]() |